FIELD: pharmaceutical chemistry.
SUBSTANCE: invention relates to the field of pharmaceutical chemistry, specifically to a method for obtaining an amino acid-based derivative characterized by formula (I) having inhibitory activity against acetylcholinesterase (AChE). The method involves the interaction of compounds characterized by the structural formulas (II), (III), (IV) and (V) in the presence of methanol, followed by treatment of the reaction mixture sequentially with chloroform and saturated NaHCO3 solution. Further evaporation of the solvent and purification of the final product by flash chromatography using a mixture of dichloromethane solvents (DCM)/MeOH with a volume ratio of solvents of 30:1, which contains 0.1 wt.% NH3, lead to the final product in the form of a syrup from pale yellow to white amorphous solid. In these formulas, R1 is benzyl, n-propyl, R2 is n-butyl, cyclohexyl, n =1, 2. The invention also relates to acetylcholinesterase (AChE) inhibitors obtained by this method, which have an increased effectiveness of inhibiting AChE.
EFFECT: expansion of the range of methods for obtaining amino acid-based derivatives.
2 cl, 42 dwg, 4 tbl, 4 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR PRODUCING AN ACETYLCHOLINESTERASE (AChE) INHIBITOR AND INHIBITOR PRODUCED BY THE METHOD | 2021 |
|
RU2779555C1 |
METHOD FOR SYNTHESIS OF 2-CARBOXY-N,N,N-TRIMETHYLETHANAMINIUM DERIVATIVE | 2021 |
|
RU2786884C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2597364C2 |
BI-ARYL-META-PYRIMIDINE KINASE INHIBITORS | 2006 |
|
RU2589878C2 |
PD-L1 ANTAGONIST COMPOUND | 2020 |
|
RU2823231C1 |
BENZO-DERIVATIVES WITH SIX-MEMBERED RING AS DPP-4 INHIBITOR AND USE THEREOF | 2015 |
|
RU2702644C2 |
GCN2 INHIBITORS AND THEIR USE | 2019 |
|
RU2811408C2 |
ARYLSULFONYLMETHYL OR ARYLSULFONAMIDE DERIVATIVES OF AROMATICS, PHARMACEUTICAL COMPOSITION BASED ON THEM AND WAY OF TREATMENT AGAINST ABNORMALITIES RESPONSIVE TO DOPAMINE D RECEPTOR LIGAND TREATMENT, WITH THEIR HELP | 2005 |
|
RU2442781C2 |
QUINAZOLINE DERIVATIVES | 2015 |
|
RU2704125C2 |
AGENT FOR INCREASING THE SENSITIVITY OF TISSUES TO INSULIN IN TYPE 2 DIABETES MELLITUS | 2022 |
|
RU2798603C1 |
Authors
Dates
2022-06-23—Published
2021-06-01—Filed